Detalhe da pesquisa
1.
Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Hematol Oncol
; 40(4): 637-644, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35141937
2.
Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
Clin Chim Acta
; 532: 72-78, 2022 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660013
3.
The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.
Front Oncol
; 12: 987965, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36249041
4.
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.
Immunotherapy
; 12(13): 997-1006, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32752910
5.
Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation.
J Immunother
; 42(3): 81-88, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30829725